PING
A poster on ZeroHedge wrote (no source, anybody want to look for it?)
2018 testing of MRNA vaccines -
“A possible concern could be that some mRNA-based vaccine platforms54,166 induce potent type I interferon responses, which have been associated not only with inflammation but also potentially with autoimmunity167,168. Thus, identification of individuals at an increased risk of autoimmune reactions before mRNA vaccination may allow reasonable precautions to be taken. Another potential safety issue could derive from the presence of extracellular RNA during mRNA vaccination. Extracellular naked RNA has been shown to increase the permeability of tightly packed endothelial cells and may thus contribute to oedema169. Another study showed that extracellular RNA promoted blood coagulation and pathological thrombus formation170. Safety will therefore need continued evaluation as different mRNA modalities and delivery systems are utilized for the first time in humans and are tested in larger patient populations”
MArch 2019 - “Therefore, mRNA holds great promises, but further insights into the mechanism of action and potency are still needed for full development of mRNA vaccines”
....As described above, the molecular impact of the innate immune response stimulated by mRNA through PAMP recognition is still not clear. Multiple efforts have been made to improve the stability and delivery efficiency of in vivo mRNA vaccine, including incorporation of 5′ and 3′ terminal untranslated regions and chemically modified nucleosides (162–164)
....Although mRNA vaccine technology has still not extensively tested in humans, publications of preclinical and early clinical tests have emerged in recent years, in which promising results were reported. This evoked the momentum of biocompanies to commercialize mRNA vaccines with great enthusiasm (167, 168). Some private funding resources and institutes have supported the research and development of mRNA vaccines (169, 170). Despite the need for further optimization of manufacturing processes to generate mRNA vaccines, these processes hopefully will be streamlined to be establish large-scale production. It is just a matter of time for RNA vaccines to be used in humans and animals”